Skip to main content
SpringerLink
Log in

The Challenge of Antiplatelet Therapy in Patients with Atrial Fibrillation and Heart Failure

  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

Abstract

Antiplatelet therapy is the cornerstone of secondary prevention in cardiovascular disease. This review focuses on the role of antiplatelet therapy in atrial fibrillation (AF) and heart failure (HF). Aspirin has a limited role in stroke prevention among most patients with AF, being of limited efficacy and not any safer than warfarin, especially in the elderly. For HF patients with AF, cardioembolism is a major cause of stroke, and antiplatelet alone would be insufficient thromboprophylaxis. Aspirin plus clopidogrel rather than aspirin alone is preferred for those AF patients who have refused any form of oral anticoagulation. For AF patients undergoing percutaneous coronary intervention, triple antithrombotic therapy (aspirin, clopidogrel, and warfarin) is recommended for the initial period (1–6 months) based on the stent type, followed by vitamin K antagonists (VKA) and clopidogrel or, alternatively VKA and aspirin for up to 12 months. In AF patients with stable vascular disease, VKA monotherapy would suffice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Potpara, T. S., Lip, G. Y., & Apostolakis, S. (2012). New anticoagulant treatments to protect against stroke in atrial fibrillation. Heart, 98, 1341–1347.

    Article  PubMed  CAS  Google Scholar 

  2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG), Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blömstrom-Lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbüchel H, Heldal M, Kristensen SD, Kolh P, Le Heuzey JY, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt FW (2012) 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace (in press).

  3. Lip, G. Y., Ponikowski, P., Andreotti, F., Anker, S. D., Filippatos, G., Homma, S., Morais, J., Pullicino, P., Rasmussen, L. H., Marin, F., Lane, D. A., & ESC Task Force. (2012). Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail, 14, 681–695.

    Article  PubMed  CAS  Google Scholar 

  4. Vemmos, K., Ntaios, G., Savvari, P., Vemmou, A. M., KorobokiE, M. E., Kounali, A., & Lip, G. Y. (2012). Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study. Eur J Heart Fail, 14, 211–218.

    Article  PubMed  Google Scholar 

  5. The Stroke Prevention in Atrial Fibrillation Investigators. (1991). Stroke prevention in atrial fibrillation study: final results. Circulation, 84, 527–539.

    Article  Google Scholar 

  6. The Stroke Prevention in Atrial Fibrillation Investigators. (1993). A differential effect of aspirin in prevention of stroke on atrial fibrillation. J Stroke Cerebrovasc Dis, 3, 181–188.

    Google Scholar 

  7. Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007). Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 146, 857–867.

    Article  PubMed  Google Scholar 

  8. Aguilar M, Hart R (2005) Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 19:CD001925.

    Google Scholar 

  9. Antithrombotic Trialists’ (ATT) Collaboration, Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., Buring, J., Hennekens, C., Kearney, P., Meade, T., Patrono, C., Roncaglioni, M. C., & Zanchetti, A. (2009). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373, 1849–1860.

    Article  PubMed  Google Scholar 

  10. ACTIVE Writing Group of the ACTIVE Investigators, Connolly, S., Pogue, J., Hart, R., Pfeffer, M., Hohnloser, S., Chrolavicius, S., Pfeffer, M., Hohnloser, S., & Yusuf, S. (2006). Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 367, 1903–1912.

    Article  PubMed  CAS  Google Scholar 

  11. Active Investigators, Connolly, S. J., Pogue, J., Hart, R. G., Hohnloser, S. H., Pfeffer, M., Chrolavicius, S., & Yusuf, S. (2009). Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med, 360, 2066–2078.

    Article  PubMed  Google Scholar 

  12. Lee, S., Shafe, A. C., & Cowie, M. R. (2011). UK stroke incidence, mortality and cardiovascular risk management 1999–2008: time-trend analysis from the General Practice Research Database. BMJ Open, 1, e000269.

    Article  PubMed  Google Scholar 

  13. Rietbrock, S., Plumb, J. M., Gallagher, A. M., & van Staa, T. P. (2009). How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. ThrombHaemost, 101, 527–534.

    CAS  Google Scholar 

  14. Olesen, J. B., Lip, G. Y., Lindhardsen, J., Lane, D. A., Ahlehoff, O., Hansen, M. L., Raunsø, J., Tolstrup, J. S., Hansen, P. R., Gislason, G. H., & Torp-Pedersen, C. (2011). Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost, 106, 739–749.

    Article  PubMed  CAS  Google Scholar 

  15. Mant, J., Hobbs, F. D., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., Murray, E., & BAFTA investigators; Midland Research Practices Network (MidReC). (2007). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet, 370, 493–503.

    Article  PubMed  CAS  Google Scholar 

  16. Jowett, S., Bryan, S., Mant, J., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Hobbs, F. D. (2011). Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation. Stroke, 42, 1717–1721.

    Article  PubMed  CAS  Google Scholar 

  17. Rash, A., Downes, T., Portner, R., Yeo, W. W., Morgan, N., & Channer, K. S. (2007). A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing, 36, 151–156.

    Article  PubMed  Google Scholar 

  18. van Walraven, C., Hart, R. G., Connolly, S., Austin, P. C., Mant, J., Hobbs, F. D., Koudstaal, P. J., Petersen, P., Perez-Gomez, F., Knottnerus, J. A., Boode, B., Ezekowitz, M. D., & Singer, D. E. (2009). Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke, 40, 1410–1416.

    Article  PubMed  Google Scholar 

  19. Sato, H., Ishikawa, K., Kitabatake, A., Ogawa, S., Maruyama, Y., Yokota, Y., Fukuyama, T., Doi, Y., Mochizuki, S., Izumi, T., Takekoshi, N., Yoshida, K., Hiramori, K., Origasa, H., Uchiyama, S., Matsumoto, M., Yamaguchi, T., Hori, M., & Japan Atrial Fibrillation Stroke Trial Group. (2006). Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke, 37, 447–451.

    Article  PubMed  CAS  Google Scholar 

  20. De Berardis, G., Lucisano, G., D’Ettorre, A., Pellegrini, F., Lepore, V., Tognoni, G., & Nicolucci, A. (2012). Association of aspirin use with major bleeding in patients with and without diabetes. JAMA, 307, 2286–2294.

    Article  PubMed  Google Scholar 

  21. Watson, T., Shantsila, E., & Lip, G. Y. (2009). Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet, 373, 155–166.

    Article  PubMed  CAS  Google Scholar 

  22. Benbir, G., Uluduz, D., Ince, B., & Bozluolcay, M. (2007). Atherothrombotic ischemic stroke in patients with atrial fibrillation. Clin Neurol Neurosurg, 109, 485–490.

    Article  PubMed  Google Scholar 

  23. Kim, Y. D., Cha, M. J., Kim, J., Lee, D. H., Lee, H. S., Nam, C. M., Nam, H. S., & Heo, J. H. (2011). Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation. Stroke, 42, 930–934.

    Article  PubMed  Google Scholar 

  24. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. (1998). Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med, 128, 639–647.

    Article  Google Scholar 

  25. Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F. J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., Antman, E. M., & TRITON-TIMI 38 Investigators. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 357, 2001–2015.

    Article  PubMed  CAS  Google Scholar 

  26. Roe, M. T., Armstrong, P. W., Fox, K. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., Ardissino, D., Nicolau, J. C., Boden, W. E., Gurbel, P. A., Ruzyllo, W., Dalby, A. J., McGuire, D. K., Leiva-Pons, J. L., Parkhomenko, A., Gottlieb, S., Topacio, G. O., Hamm, C., Pavlides, G., Goudev, A. R., Oto, A., Tseng, C. D., Merkely, B., Gasparovic, V., Corbalan, R., Cinteză, M., McLendon, R. C., Winters, K. J., Brown, E. B., Lokhnygina, Y., Aylward, P. E., Huber, K., Hochman, J. S., Ohman, E. M., & TRILOGY ACS Investigators. (2010). Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med, 367, 1297–1309.

    Article  Google Scholar 

  27. James, S. K., Roe, M. T., Cannon, C. P., Cornel, J. H., Horrow, J., Husted, S., Katus, H., Morais, J., Steg, P. G., Storey, R. F., Stevens, S., Wallentin, L., Harrington, R. A., & Study Group, P. L. A. T. O. (2011). Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ, 342, d3527. doi:10.1136/bmj.d3527.

    Article  PubMed  Google Scholar 

  28. Holmes, D. R., Jr., Dehmer, G. J., Kaul, S., Leifer, D., O’Gara, P. T., & Stein, C. M. (2010). ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol, 56, 321–341.

    Article  PubMed  CAS  Google Scholar 

  29. Authors/Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Di Mario, C., Dickstein, K., Ducrocq, G., Fernandez-Aviles, F., Gershlick, A. H., Giannuzzi, P., Halvorsen, S., Huber, K., Juni, P., Kastrati, A., Knuuti, J., Lenzen, M. J., Mahaffey, K. W., Valgimigli, M., Van’t Hof, A., Widimsky, P., Zahger, D., ESC Committee for Practice Guidelines (CPG), Bax, J. J., Baumgartner, H., Ceconi, C., Dean, V., Deaton, C., Fagard, R., Funck-Brentano, C., Hasdai, D., Hoes, A., Kirchhof, P., Knuuti, J., Kolh, P., McDonagh, T., Moulin, C., Popescu, B. A., Reiner, Z., Sechtem, U., Sirnes, P. A., Tendera, M., Torbicki, A., Vahanian, A., Windecker, S., Document Reviewers, Hasdai, D., Astin, F., Aström-Olsson, K., Budaj, A., Clemmensen, P., Collet, J. P., Fox, K. A., Fuat, A., Gustiene, O., Hamm, C. W., Kala, P., Lancellotti, P., Maggioni, A. P., Merkely, B., Neumann, F. J., Piepoli, M. F., Van de Werf, F., Verheugt, F., & Wallentin, L. (2012). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J, 33, 2569–2619.

    Article  PubMed  CAS  Google Scholar 

  30. Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H. C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., Talajic, M., Zhu, J., Pais, P., Budaj, A., Parkhomenko, A., Jansky, P., Commerford, P., Tan, R. S., Sim, K. H., Lewis, B. S., Van Mieghem, W., Lip, G. Y., Kim, J. H., Lanas-Zanetti, F., Gonzalez-Hermosillo, A., Dans, A. L., Munawar, M., O’Donnell, M., Lawrence, J., Lewis, G., Afzal, R., Yusuf, S., & AVERROES Steering Committee and Investigators. (2011). Apixaban in patients with atrial fibrillation. N Engl J Med, 364, 806–817.

    Article  PubMed  CAS  Google Scholar 

  31. Diener, H. C., Eikelboom, J., Connolly, S. J., Joyner, C. D., Hart, R. G., Lip, G. Y., O’Donnell, M., Hohnloser, S. H., Hankey, G. J., Shestakovska, O., Yusuf, S., & AVERROES Steering Committee and Investigators. (2012). Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol, 11, 225–231.

    Article  PubMed  CAS  Google Scholar 

  32. Hansen, M. L., Sørensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunsø, J., Gadsbøll, N., Gislason, G. H., Folke, F., Andersen, S. S., Schramm, T. K., Abildstrøm, S. Z., Poulsen, H. E., Køber, L., & Torp-Pedersen, C. (2010). Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med, 170, 1433–1441.

    Article  PubMed  CAS  Google Scholar 

  33. Lip, G. Y., Huber, K., Andreotti, F., Arnesen, H., Airaksinen, K. J., Cuisset, T., Kirchhof, P., Marín, F., & European Society of Cardiology Working Group on Thrombosis. (2010). Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost, 103, 13–28.

    Article  PubMed  CAS  Google Scholar 

  34. Lane, D. A., Kamphuisen, P. W., Minini, P., Büller, H. R., & Lip, G. Y. (2011). Bleeding risk in patients with atrial fibrillation: the AMADEUS study. Chest, 140, 146–155.

    Article  PubMed  Google Scholar 

  35. De Ferrari, G. M., Klersy, C., Ferrero, P., Fantoni, C., Salerno-Uriarte, D., Manca, L., Devecchi, P., Molon, G., Revera, M., Curnis, A., Sarzi Braga, S., Accardi, F., Salerno-Uriarte, J. A., & ALPHA Study Group. (2007). Atrial fibrillation in heart failure patients: prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur J Heart Fail, 9, 502–509.

    Article  PubMed  Google Scholar 

  36. Dickstein, K., Bogale, N., Priori, S., Auricchio, A., Cleland, J. G., Gitt, A., Limbourg, T., Linde, C., van Veldhuisen, D. J., Brugada, J., & Scientific Committee, National Coordinators. (2009). The European cardiac resynchronization therapy survey. Eur Heart J, 30, 2450–2460.

    Article  PubMed  Google Scholar 

  37. Nieminen, M. S., Brutsaert, D., Dickstein, K., Drexler, H., Follath, F., Harjola, V. P., Hochadel, M., Komajda, M., Lassus, J., Lopez-Sendon, J. L., Ponikowski, P., Tavazzi, L., & EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. (2006). EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart, J27, 2725–2736.

    Article  Google Scholar 

  38. Mulder, B. A., Van Veldhuisen, D. J., Crijns, H. J., Böhm, M., Cohen-Solal, A., Babalis, D., Roughton, M., Flather, M. D., Coats, A. J., & Van Gelder, I. C. (2012). Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. Eur J Heart Fail, 14, 1171–1178.

    Article  PubMed  CAS  Google Scholar 

  39. Dahlstrom, U., Hakansson, J., Swedberg, K., & Waldenstrom, A. (2009). Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden. Eur J Heart Fail, 11, 92–98.

    Article  PubMed  Google Scholar 

  40. Holmström A, Sigurjonsdottir R, Edner M, Jonsson A, Dahlström U, Fu ML (2012) Increased comorbidities in heart failure patients ≥85 years but declined from >90 years: data from the Swedish Heart Failure Registry. Int J Cardiol (in press)

  41. de Peuter, O. R., Lip, G. Y., Souverein, P. C., Klungel, O. H., de Boer, A., Büller, H. R., & Kamphuisen, P. W. (2011). Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study. Eur J Heart Fail, 489.

  42. Witt, B. J., Gami, A. S., Ballman, K. V., Brown, R. D., Jr., Meverden, R. A., Jacobsen, S. J., & Roger, V. L. (2007). The incidence of ishcemic stroke in chronic heart failure: a meta-analysis. J Card Fail, 13, 489–496.

    Article  PubMed  Google Scholar 

  43. Albert, V. P., Bos, M. J., Koudstaal, P. J., Hofman, A., Witteman, J. C., Stricker, B. H., & Breteler, M. M. (2010). Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol, 25, 807–812.

    Article  Google Scholar 

  44. Kannel, W. B., Wolf, P. A., & Verter, J. (1983). Mainfestations of coronary disease predisposing to stroke: the Framingham Study. JAMA, 250, 2942–2946.

    Article  PubMed  CAS  Google Scholar 

  45. Lip GY, Rasmussen LH, Skjøth F, Overvad K, Larsen TB (2012) Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. BMJ Open. 2:e000975. doi: 10.1136/bmjopen-2012-000975.

  46. Banerjee, A., Taillandier, S., Olesen, J. B., Lane, D. A., Lallemand, B., Lip, G. Y., & Fauchier, L. (2012). Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail, 14, 295–301.

    Article  PubMed  Google Scholar 

  47. Shantsila, E., & Lip, G. Y. (2011). The risk of thromboembolism in heart failure: does it merit anticoagulation therapy? Am J Cardiol, 107, 558–560.

    Article  PubMed  Google Scholar 

  48. Lip, G. Y., & Gibbs, C. R. (1999). Does heart failure confer a hypercoagulable state? Virchow’s triad revisited. J Am CollCardiol, 33, 1424–1426.

    Article  CAS  Google Scholar 

  49. Freudenberger, R. S., Schumaecker, M. M., & Homma, S. (2010). What is the appropriate approach to prevention of thromboembolism in heart failure? Thromb Haemost, 103, 489–495.

    Article  PubMed  CAS  Google Scholar 

  50. Vandvik, P. O., Lincoff, A. M., Gore, J. M., Gutterman, D. D., Sonnenberg, F. A., Alonso-Coello, P., Akl, E. A., Lansberg, M. G., Guyatt, G. H., Spencer, F. A., & American College of Chest Physicians. (2012). Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141(2 Suppl), e637S–e668S.

    Article  PubMed  CAS  Google Scholar 

  51. Cleland, J. G., Findlay, I., Jafri, S., Sutton, G., Falk, R., Bulpitt, C., Prentice, C., Ford, I., Trainer, A., & Poole-Wilson, P. A. (2004). The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart, J148, 157–164.

    Article  Google Scholar 

  52. Massie, B. M., Collins, J. F., Ammon, S. E., Armstrong, P. W., Cleland, J. G., Ezekowitz, M., Jafri, S. M., Krol, W. F., O’Connor, C. M., Schulman, K. A., Teo, K., Warren, S. R., & WATCH Trial Investigators. (2009). Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation, 119, 1616–1624.

    Article  PubMed  CAS  Google Scholar 

  53. Cokkinos, D. V., Haralabopoulos, G. C., Kostis, J. B., Toutouzas, P. K., & HELAS Investigators. (2006). Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail, 8, 428–432.

    Article  PubMed  CAS  Google Scholar 

  54. Homma, S., Thompson, J. L., Pullicino, P. M., Levin, B., Freudenberger, R. S., Teerlink, J. R., Ammon, S. E., Graham, S., Sacco, R. L., Mann, D. L., Mohr, J. P., Massie, B. M., Labovitz, A. J., Anker, S. D., Lok, D. J., Ponikowski, P., Estol, C. J., Lip, G. Y., Di Tullio, M. R., Sanford, A. R., Mejia, V., Gabriel, A. P., del Valle, M. L., Buchsbaum, R., & Investigators, W. A. R. C. E. F. (2012). Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med, 366, 1859–1869.

    Article  PubMed  CAS  Google Scholar 

  55. McMurray, J. J., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., Gomez-Sanchez, M. A., Jaarsma, T., Køber, L., Lip, G. Y., Maggioni, A. P., Parkhomenko, A., Pieske, B. M., Popescu, B. A., Rønnevik, P. K., Rutten, F. H., Schwitter, J., Seferovic, P., Stepinska, J., Trindade, P. T., Voors, A. A., Zannad, F., Zeiher, A., ESC Committee for Practice Guidelines (CPG), Bax, J. J., Baumgartner, H., Ceconi, C., Dean, V., Deaton, C., Fagard, R., Funck-Brentano, C., Hasdai, D., Hoes, A., Kirchhof, P., Knuuti, J., Kolh, P., McDonagh, T., Moulin, C., Popescu, B. A., Reiner, Z., Sechtem, U., Sirnes, P. A., Tendera, M., Torbicki, A., Vahanian, A., Windecker, S., Document Reviewers, McDonagh, T., Sechtem, U., Bonet, L. A., Avraamides, P., Ben Lamin, H. A., Brignole, M., Coca, A., Cowburn, P., Dargie, H., Elliott, P., Flachskampf, F. A., Guida, G. F., Hardman, S., Iung, B., Merkely, B., Mueller, C., Nanas, J. N., Nielsen, O. W., Orn, S., Parissis, J. T., & Ponikowski, P. (2012). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail, 14, 803–869.

    Article  PubMed  CAS  Google Scholar 

  56. Ahrens, I., Lip, G. Y., & Peter, K. (2010). New oral anticoagulant drugs in cardiovascular disease. ThrombHaemost, 104, 49–60.

    CAS  Google Scholar 

  57. Petersen, P., Boysen, G., Godtfredsen, J., Andersen, E. D., & Andersen, B. (1989). Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet, 1, 175–179.

    Article  PubMed  CAS  Google Scholar 

  58. Hellemons, B. S., Langenberg, M., Lodder, J., Vermeer, F., Schouten, H. J., Lemmens, T., van Ree, J. W., & Knottnerus, J. A. (1999). Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomized controlled trial comparing two intensities of coumarin with aspirin. BMJ, 319, 958–964.

    Article  PubMed  CAS  Google Scholar 

  59. Pérez-Gómez, F., Alegría, E., Berjón, J., Iriarte, J. A., Zumalde, J., Salvador, A., Mataix, L., & Investigators, N. A. S. P. E. A. F. (2004). Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am CollCardiol, 44, 1557–1566.

    Article  Google Scholar 

  60. Gulløv, A. L., Koefoed, B. G., Petersen, P., Pedersen, T. S., Andersen, E. D., Godtfredsen, J., & Boysen, G. (1989). Fixed minidose warfarin and aspirin alone and in combination vs. adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med, 158, 1513–1521.

    Article  Google Scholar 

  61. The Stroke Prevention in Atrial Fibrillation Investigators. (1994). Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet, 343, 687–691.

    Google Scholar 

Download references

Competing interests

Professor Lip has served as a consultant for Bayer, Astellas, Merck, Sanofi, BMS/Pfizer, Daiichi-Sankyo, Biotronik, Portola, and BoehringerIngelheim and has been on the speakers bureau for Bayer, BMS/Pfizer, Boehringer-Ingelheim, and Sanofi Aventis. Drs. Apostolakis and Guo—none declared.

Author information

Authors and Affiliations

  1. Haemostasis, Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Science, City Hospital, Birmingham, B18 7QH, UK

    Gregory Y. H. Lip & Stavros Apostolakis

  2. Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China

    Yutao Guo

Authors
  1. Yutao Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory Y. H. Lip
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stavros Apostolakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stavros Apostolakis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guo, Y., Lip, G.Y.H. & Apostolakis, S. The Challenge of Antiplatelet Therapy in Patients with Atrial Fibrillation and Heart Failure. J. of Cardiovasc. Trans. Res. 6, 388–397 (2013). https://doi.org/10.1007/s12265-012-9427-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12265-012-9427-y

Keywords

Search

Navigation